Andrew Bradbury, MD, PhDChief Scientific Officer at Specifica
Andrew Bradbury is Chief Scientific Officer of Specifica, a company he founded in 2016, after retiring as Group Leader at LANL. He trained in medicine at the Universities of Oxford and London and received his PhD from the University of Cambridge at the MRC Laboratory of Molecular Biology, under the guidance of Cesar Milstein. He has worked in antibody engineering for over thirty years. Specifica's mission is to provide companies developing therapeutic antibodies with the world’s best antibody selection platform.